Skip to main content

Table 2 Summary of the literature: Frequency of MSI in ovarian cancer. The total number of MSI, the number of MS markers used for the analysis and the number of MSI per histological subtype (if mentioned) is given for each study.

From: Mismatch repair and treatment resistance in ovarian cancer

  MSI MS markers Histology
    NCI-CP total SE EN CC MU MM PD
Helleman et al. 0/75 (0%) 2 2 0/36 (0%) 0/13 (0%) 0/3 (0%) 0/10 (0%) 0/8 (0%) 0/3 (0%)
Mesquita et al.2005 0/34 (0%) 1 2 0/26 (0%) - 0/8 (0%) - - -
Gifford et al. 2004 2/138 (1%) 3 6 Not mentioned
Catasus et al. 2004 5/54 (9%) 5 5 EN, CC and MM histology
Cai et al.2004 6/42 (14%) 5 5 - - 6/42 (14%) - - -
Liu et al.2004 15/74 (20%) 4 4 - 15/74 (20%) - - - -
Singer et al.2004 6/75 (8%) 5 11 5/53 (9%) 1/14 (7%) 0/3 (0%) 0/5 (0%) - -
Geisler et al.2003 21/125 (17%) 5 6 10/69 (14%) 6/22 (27%) 0/4 (0%) 2/9 (22%) - 1/2 (50%)
Watanabe et al. 2001 2/24 (8%) 5 10 Not mentioned
Sood et al. 2001 13/109 (12%) 5 14 Not mentioned
Gras et al.2001 7/76 (9%) 5 10 0/17 (0%) 1/48 (2%) 1/8 (13%) 0/2 (0%) 0/6 (0%) -
Buller et al. 2001 22/56 (39%) 5 6 Not mentioned
Chiaravalli et al.2001 3/16 (19%) 2 3 0/8 (0%) 1/2 (50%) - 2/4 (50%) - 0/2 (0%)
Ohwada et al.2000 15/61 (25%) 1 5 4/32 (13%) - - 11/29 (38%) - -
Allen et al.2000 1/25 (4%) 2 4 1/16 (6%) 0/2 (0%) 0/2 (0%) 0/1 (0%) - 0/4 (0%)
Colella et al. 1998 3/20 (15%) 0 3 Not mentioned
Sood et al. 1997 13/78 (17%) 1 9 Not mentioned
Sood et al. 1996 11/68 (16%) 1 9 34 serous and 34 not serous
Tangir et al.1996 2/31 (6%) 0 13 2/31 (6%) - - - - -
Arzimanoglou et al. 1996 11/90 (12%) 1 3 Not mentioned
Fujita et al.1995 7/44 (16%) 0 4 2/22 (9%) 5/10 (50%) 0/4 (0%) 0/8 (0%) - -
Total 165/1315 (13%)    24/310 (8%) 29/185 (16%) 7/74 (9%) 15/68 (22%) 0/14 (0%) 1/11 (9%)
  1. Abbreviations: SE serous, EN endometrioid, CC clear cell, MU mucinous, MM mixed mullerian, PD poorly differentiated, - not present, MS microsatellite, NCI-CP National Cancer Institute Consensus Panel.